ARDELYX, INC. Deferred Income Tax Expense (Benefit)
ARDELYX, INC. (ARDX) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-19
- ARDELYX, INC. deferred income tax expense (benefit) for fiscal 2025 was $0.00.
- ARDELYX, INC. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- ARDELYX, INC. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- ARDELYX, INC. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-20 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-22 |
| 2020-12-31 | $0.00 10-K · filed 2023-03-02 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2017-12-31 | -$30.00K 10-K · filed 2020-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |